tiprankstipranks
Beam Therapeutics, Inc. (BEAM)
NASDAQ:BEAM
US Market
BEAM
Beam Therapeutics
RESEARCH TOOLSreports
Want to see BEAM full AI Analyst Report?

Beam Therapeutics (BEAM) Stock News & Sentiment

2,243 Followers
Beam Therapeutics: Buy Rating Reaffirmed as Clinical Momentum Builds and $68 Price Target Remains Unchanged
Premium
Ratings
Beam Therapeutics: Buy Rating Reaffirmed as Clinical Momentum Builds and $68 Price Target Remains Unchanged
7d ago
BEAM
Analyst Maintains Buy on Beam Therapeutics, Reiterates $75 Price Target Amid Pipeline Progress and De-Risking Milestones
Premium
Ratings
Analyst Maintains Buy on Beam Therapeutics, Reiterates $75 Price Target Amid Pipeline Progress and De-Risking Milestones
10d ago
BEAM
Beam Therapeutics: Compelling BEAM-302 Data and Manageable Safety Profile Underpin Buy Rating and Favorable Risk‑Reward
Premium
Ratings
Beam Therapeutics: Compelling BEAM-302 Data and Manageable Safety Profile Underpin Buy Rating and Favorable Risk‑Reward
1M ago
BEAM
Beam Therapeutics: BEAM-302’s Differentiated AATD Profile and Accelerated Path Support Buy Rating and $80 Target
Premium
Ratings
Beam Therapeutics: BEAM-302’s Differentiated AATD Profile and Accelerated Path Support Buy Rating and $80 Target
2M ago
BEAM
Beam Therapeutics Restructures Base-Editing Licensing After Bio Palette Exit
Premium
Company Announcements
Beam Therapeutics Restructures Base-Editing Licensing After Bio Palette Exit
3M ago
8K
BEAM
Beam Therapeutics Earnings Call Highlights PKU Pivot
Premium
Company Announcements
Beam Therapeutics Earnings Call Highlights PKU Pivot
3M ago
BEAM
Beam Therapeutics: Advancing Interventional Genetics With Strong Balance Sheet and Multiple Near-Term Catalysts Supporting Buy Rating
Premium
Ratings
Beam Therapeutics: Advancing Interventional Genetics With Strong Balance Sheet and Multiple Near-Term Catalysts Supporting Buy Rating
3M ago
BEAM
More BEAM News >

BEAM News on the Web

Beam Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript
GuruFocus News
Neutral
Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances
MarketBeat
Bullish
BEAM-302 Shows Durable Gene Correction in Alpha-1 Antitrypsin Deficiency—New Data Points to One-Time Therapy Potential
Market Chameleon
Neutral
Beam Therapeutics presents Phase 1/2 data for BEAM-302
TipRanks News
Bullish
Beam Therapeutics Stock Stumbles After Post-Rally Shakeout
TipRanks News
Bearish
Beam Therapeutics: Buy Rating Reaffirmed as Clinical Momentum Builds and $68 Price Target Remains Unchanged
TipRanks News
Bullish
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks News
Bullish
Beam Therapeutics price target lowered to $39 from $40 at Bernstein
TipRanks News
Bullish

News Score - Last 7 Days

Positive
BEAM
Sector Average
Media Buzz
This Week4 articles
Weekly Average5 articles
News Sentiment
This Week79%
Sector Average76%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is BEAM’s Media Buzz Sentiment?
4 articles about BEAM were published this week. In an average week, 5 articles are published.
    What is BEAM’s weekly average amount of articles?
    In an average week, 5 articles about BEAM are published.
      What is BEAM’s News Sentiment?
      79% of articles about BEAM were positive this week, compared to its sector average of 76%.
        Healthcare Stocks that are Trending in the News
        GOSSGossamer Bio
        RLAYRelay Therapeutics
        CGENCompugen
        PROKProKidney
        ROIVRoivant Sciences
        Showing the stocks with the most bullish news sentiment over the past week